PFIZER INC (PFE): M&A transaction — Pfizer completes $43B acquisition of Seagen at $229/share, expanding oncology portfolio

PFIZER INC

Pfizer acquired Seagen for $229 per share in cash, total enterprise value of ~$43 billion.
Acquisition adds Seagen's four in-line ADC medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) to Pfizer's oncology portfolio.
Pfizer's oncology pipeline doubles to 60 programs; now includes over 25 approved medicines across more than 40 indications.
To address FTC concerns, Pfizer irrevocably donates U.S. royalties from Bavencio (avelumab) to American Association for Cancer Research.
Pfizer expects oncology to be a significant growth driver and contribute to near- and long-term financial goals.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

PFIZER INC completed an acquisition involving Seagen Inc. for $229.00 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).

Action: acquisition
Counterparty: Seagen Inc.
Consideration: $229.00 in cash per share, for a total enterprise value of approximately $43 billion
Closing: 2023-12-14

Exact text from the filing

Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.

View on SEC.gov

95 m&a transactions filed in the last 30 days. Browse all m&a transactions →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0001193125-23-294930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.